Drug intelligence / Profile preview

AD-2072

Development stage: Unknown
Lead developer: Yuhan
Modality: Small Molecules
Administration: Oral

Overview

AD-2072 is a small molecule drug developed by Yuhan Corp. and further investigated by Addpharma. It is being studied primarily for the treatment of cardiovascular diseases, specifically hypertension and hyperlipidemias. The mechanism of action for AD-2072 remains unknown, and it does not represent a novel mechanism of action compared to existing therapies. Clinical development has reached Phase 1, with studies evaluating its pharmacokinetic interactions when co-administered with other agents such as AD-2071 in healthy volunteers[1][2][3][4][5]. The drug is administered orally.

Beyond the preview

Go deeper on AD-2072.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-2072.

Explore the full profile